Results 51 to 60 of about 82 (71)

Análise e projeto do conversor Boost-Quadrático-Buck associado à célula de comutação quase ressonante Single-Switch

Welker Silva
core   +1 more source

Some of the next articles are maybe not open access.

Related searches:

mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron

Cell, 2022
Matthew Gagne, Kathryn E Foulds, Shayne F Andrew   +2 more
exaly  

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

Lancet, The, 2021
Sue Charlton, Andrea M Collins, Saul N Faust   +2 more
exaly  

INCATE: a partnership to boost the antibiotic pipeline

Nature Reviews Drug Discovery, 2022
exaly  

Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial

Lancet, The, 2023
exaly  

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Lancet, The, 2020
Maheshi N Ramasamy, Pedro M Folegatti, Daniel R Owens   +2 more
exaly  

Using immunotherapy to boost the abscopal effect

Nature Reviews Cancer, 2018
Wilfred Ngwa, Jonathan D Schoenfeld, Sandra Demaria   +2 more
exaly  

Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial

Lancet, The, 2004
David W Andrews, Minesh P Mehta
exaly  

Breast radiotherapy for non-low-risk ductal carcinoma in situ: to boost or not to boost? – Authors' reply

Lancet, The, 2023
exaly  

Breast radiotherapy for non-low-risk ductal carcinoma in situ: to boost or not to boost?

Lancet, The, 2023
exaly